Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 HERTFORDSHIRE, England and...
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020...
Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn Pfizer Announces Record Date for the Proposed Transaction PR...
Pfizer Announces Record Date for the Proposed Transaction Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Federal Trade Commission (the “FTC”) accepted a...
Mylan and Development Partner, Synthon, Win Significant European Patent Office Ruling Related to Copaxone® 40mg/mL Decision clears legal pathway to expand access for patients living with multiple...
Mylan and Pfizer Receive European Commission Approval for Proposed Combination of Mylan and Upjohn The Companies Have Also Received Approvals in Australia and New Zealand; Combination on Track to...
Mylan to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020 HERTFORDSHIRE, England and PITTSBURGH...
Mylan to Present at the BofA Securities Virtual Global Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020 HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020...
Mylan to Acquire Aspen's Thrombosis Business in Europe Acquisition further complements and expands Mylan's complex injectables offering and presence in hospitals Transaction expected to be...
Mylan and Biocon Biologics Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes Semglee available in vial and pen presentations...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
